Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Evid Based Complement Alternat Med. 2013;2013:706125. doi: 10.1155/2013/706125. Epub 2013 Apr 24.
Background. Tianma Gouteng Yin (TGY) is widely used for essential hypertension (EH) as adjunctive treatment. Many randomized clinical trials (RCTs) of TGY for EH have been published. However, it has not been evaluated to justify their clinical use and recommendation based on TCM zheng classification. Objectives. To assess the current clinical evidence of TGY as adjunctive treatment for EH with liver yang hyperactivity syndrome (LYHS) and liver-kidney yin deficiency syndrome (LKYDS). Search Strategy. 7 electronic databases were searched until November 20, 2012. Inclusion Criteria. RCTs testing TGY combined with antihypertensive drugs versus antihypertensive drugs were included. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane standards. Results. 22 RCTs were included. Methodological quality was generally low. Except diuretics treatment group, blood pressure was improved in the other 5 subgroups; zheng was improved in angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), and "CCB + ACEI" treatment groups. The safety of TGY is still uncertain. Conclusions. No confirmed conclusion about the effectiveness and safety of TGY as adjunctive treatment for EH with LYHS and LKYDS could be made. More rigorous trials are needed to confirm the results.
背景。天麻钩藤饮（TGY）广泛用于治疗原发性高血压（EH），作为辅助治疗。已经发表了许多关于 TGY 治疗 EH 的随机对照试验（RCT）。然而，尚未根据中医证型分类对其进行评估，以证明其临床应用和推荐的合理性。目的。评估 TGY 作为辅助治疗肝阳上亢证（LYHS）和肝肾阴虚证（LKYDS）EH 的临床证据。搜索策略。直到 2012 年 11 月 20 日，检索了 7 个电子数据库。纳入标准。纳入了测试 TGY 联合降压药与降压药的 RCT。数据提取和分析。根据 Cochrane 标准进行研究选择、数据提取、质量评估和数据分析。结果。纳入了 22 项 RCT。方法学质量普遍较低。除利尿剂治疗组外，其他 5 个亚组的血压均有改善；在血管紧张素转换酶抑制剂（ACEIs）、钙通道阻滞剂（CCBs）和“CCB+ACEI”治疗组中，证得到改善。TGY 的安全性仍不确定。结论。对于 TGY 作为辅助治疗 LYHS 和 LKYDS EH 的有效性和安全性，尚无明确的结论。需要更严格的试验来证实这些结果。
